Do You Want to Know if You Have Neutralizing Antibodies to COVID-19?

Post Infection Convalescence • Post Vaccination • Post Monoclonal Antibodies Treatment

Post Infection Convalescence

Serum-IgG Responses to SARS-CoV-2 After Mild and Severe COVID-19 Infection

Patients with severe symptoms and patients with mild symptoms of COVID-19 both develop SARS-CoV-2-specific IgG antibodies in serum (according to clinical trials). Patients with severe COVID-19 both seroconvert earlier and develop higher concentrations of SARS-CoV-2-specific IgG than patients with mild symptoms. Seroconverted patients with both mild and severe symptoms should still have detectable IgG levels after more than 75 days. A small percentage of patients with mild disease failed to produce detectable levels of IgG (more than 90 days PSO), but virus-neutralizing antibodies (NAbs) against SARS-CoV-2 were detected in all of these patients in the trials.

Concentrations of serum IgG over time in patients with Severe (Red) and Mild (Blue) disease (Cut-off for positive sample indicated by dotted line) in clinical trial:

IgM Antibody Testing

PLOS ONE | https://doi.org/10.1371/journal.pone.0241104 October 21, 2020

Maximum concentrations of serum IgG in early (1–35 days) and late (>75 days) follow-up post symptom onset (ns P>0.05, ** P<0.01)

IgM Antibody Testing

PLOS ONE | https://doi.org/10.1371/journal.pone.0241104 October 21, 2020

Post Vaccination

Assessing mRNA Vaccine’s Level of Protection Against Covid-19

SARS-CoV-2 Antibody-Binding and Neutralization Responses Following mRNA Vaccination

We have a diverse group of people who are getting vaccinated, different age groups with different underlying health conditions. We need to assess the long-term durability of immunogenicity and the magnitude of antibody, cellular, and memory responses for at least 12 months following the second vaccination.

A two-dose regimen of vaccination should confer 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar throughout all available mRNA viral vaccines in the clinical trials.

Reciprocal end-point binding IgG titers on receptor-binding domain (RBD) enzyme-linked immunosorbent assay (ELISA) in clinical trial:

The New England Journal of Medicine

Post Monoclonal Antibodies Treatment

Virus neutralizing monoclonal antibodies (VNMA) are made in a laboratory to act like natural antibodies to limit the amount of virus in your body. VNMA infusion is specifically directed against the spike protein of SARS-CoV-2 and administered to patients with recently diagnosed Covid-19. They are designed to block the virus’ attachment and entry into human cells.

VNMA treatment with bamlanivimab or casirivimab/imdevimab is used for people who have mild to moderate symptoms. Analysis in clinical trials after infusion of VNMA appeared to accelerate the natural decline in viral load.

All tests are performed in Ayass BioScience, LLC. Ayass BioScience, LLC (DBA Ayass Laboratory, LLC) is a CLIA certified laboratory. If you have any questions about Ayass BioScience, LLC COVID-19 Testing, Call Our Hotline at 469-415-1600 or fill out our contact form on the bottom of this page. We will answer any question you might have.